[go: up one dir, main page]

PE20161132A1 - Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol - Google Patents

Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol

Info

Publication number
PE20161132A1
PE20161132A1 PE2016000969A PE2016000969A PE20161132A1 PE 20161132 A1 PE20161132 A1 PE 20161132A1 PE 2016000969 A PE2016000969 A PE 2016000969A PE 2016000969 A PE2016000969 A PE 2016000969A PE 20161132 A1 PE20161132 A1 PE 20161132A1
Authority
PE
Peru
Prior art keywords
aerosol
composition
formoterol
cosolvent
stabilizer
Prior art date
Application number
PE2016000969A
Other languages
English (en)
Inventor
Sauro Bonelli
Diego Copelli
Enrico Zambelli
Francesca Usberti
Alberi Massimiliano Dagli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49886776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20161132(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PE20161132A1 publication Critical patent/PE20161132A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/007—Mechanical counters
    • A61M15/0071—Mechanical counters having a display or indicator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
    • B65D83/141—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant specially adapted for specific contents or propellants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
    • B65D83/44—Valves specially adapted for the discharge of contents; Regulating devices
    • B65D83/52—Metering valves; Metering devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A61M2039/226—Spindles or actuating means

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mechanical Engineering (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Se refiere a una composicion farmaceutica en solucion para aerosol para utilizar con un inhalador presurizado de dosis medida, que comprende: a) bromuro de glicopirronio con una dosificacion entre 5 y 26 ug por accionamiento; b) formoterol, o una sal del mismo o un solvato de dicha sal, con una dosificacion entre 1 y 25 ug por accionamiento; c) un propelente que consiste en un HFA; d) un cosolvente; y e) un acido mineral como estabilizante en una cantidad util. Dicha composicion esta contenida en un envase de aerosol provisto de una valvula dosificadora que tiene por lo menos una junta de caucho butilico. En un aspecto preferido, el acido mineral es acido clorhidrico 1M, en una cantidad entre 0,15 y 0,28 ug/ul como estabilizante; y el cosolvente es etanol. En otro aspecto, dicha composicion comprende opcionalmente uno o mas ingredientes farmaceuticamente activos, seleccionados entre beta–2 agonistas; corticoesteroides para inhalacion (dipropionato de beclometasona, budesonida, propionato de fluticasona, triamcinolona, prednisona, entre otros); agentes antimuscarinicos, e inhibidores de fosfodiesterasa–4. El almacenamiento de dicha composicion en envases de aerosol provistos de una valvula dosificadora como se ha senalado anteriormente, minimiza las cantidades de productos de degradacion (particularmente DP3) durante su vida de estante, aun por debajo del umbral de deteccion despues del almacenamiento en condiciones severas de temperatura y humedad
PE2016000969A 2013-12-30 2014-12-23 Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol PE20161132A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13199783 2013-12-30

Publications (1)

Publication Number Publication Date
PE20161132A1 true PE20161132A1 (es) 2016-11-02

Family

ID=49886776

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000969A PE20161132A1 (es) 2013-12-30 2014-12-23 Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol

Country Status (36)

Country Link
US (3) US20150182459A1 (es)
EP (1) EP3096737B1 (es)
JP (2) JP6534397B2 (es)
KR (1) KR101865131B1 (es)
CN (2) CN105848642A (es)
AR (2) AR098983A1 (es)
AU (1) AU2014375300B2 (es)
BR (1) BR112016014586A2 (es)
CA (1) CA2935302C (es)
CL (1) CL2016001652A1 (es)
CY (1) CY1120205T1 (es)
DK (1) DK3096737T3 (es)
EA (1) EA033228B1 (es)
ES (1) ES2666905T4 (es)
GE (2) GEAP201814192A (es)
HR (1) HRP20180944T1 (es)
HU (1) HUE039359T2 (es)
IL (1) IL246502B (es)
LT (1) LT3096737T (es)
MA (1) MA39154A1 (es)
ME (1) ME03076B (es)
MX (1) MX368834B (es)
MY (1) MY176191A (es)
NO (1) NO3096737T3 (es)
PE (1) PE20161132A1 (es)
PH (1) PH12016501269B1 (es)
PL (1) PL3096737T3 (es)
PT (1) PT3096737T (es)
RS (1) RS57269B1 (es)
SA (1) SA516371428B1 (es)
SG (1) SG11201605309UA (es)
SI (1) SI3096737T1 (es)
TN (1) TN2016000262A1 (es)
TR (1) TR201809356T4 (es)
UA (1) UA117846C2 (es)
WO (1) WO2015101575A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2515854E (pt) 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
DK2515855T6 (da) 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
WO2011076841A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
TN2016000262A1 (en) * 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
CA2935305C (en) * 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
GB201520862D0 (en) * 2015-11-25 2016-01-13 Jagotec Ag Pharmaceutical composition
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
PE20191043A1 (es) 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
EP3860580A4 (en) * 2018-10-01 2022-07-20 Kindeva Drug Delivery L.P. FORMULATION AND AEROSOL CARTRIDGES, INHALATORS AND THE LIKE CONTAINING THE FORMULATION
CN114206317A (zh) * 2019-07-12 2022-03-18 金德瓦药物控释有限公司 气雾剂制剂、含有该制剂的罐和吸入器以及使用方法
WO2021033081A1 (en) * 2019-08-16 2021-02-25 Glenmark Pharmaceutical Limited Stable aerosol composition for inhalation comprising glycopyrronium, formoterol and corticosteroid
CN112438966B (zh) * 2019-08-30 2022-08-26 四川普锐特药业有限公司 一种医用定量吸入气雾剂
KR102835735B1 (ko) 2019-12-02 2025-07-21 키에시 파르마슈티시 엣스. 피. 에이. 가압 정량 흡입기를 위한 스테인리스 스틸 캔
US20210205223A1 (en) * 2020-01-04 2021-07-08 Cai Gu Huang Propellant-free formulation for inhalation
PE20221867A1 (es) * 2020-01-28 2022-12-02 Chiesi Farm Spa Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada
AU2021223587A1 (en) * 2020-02-20 2022-09-29 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
CN115989032A (zh) 2020-07-31 2023-04-18 化学研究有限公司 用于吸入施用的组合疗法
JP2023546025A (ja) * 2020-10-09 2023-11-01 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧定量吸入器のための医薬製剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
GB0315791D0 (en) * 2003-07-07 2003-08-13 3M Innovative Properties Co Two component molded valve stems
CA2550841C (en) * 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
ATE404185T1 (de) 2004-05-13 2008-08-15 Chiesi Farma Spa Medizinische aerosolformulierungen mit verbesserter chemischer stabilität
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2201934A1 (en) * 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
CA2764867C (en) * 2009-06-09 2016-05-17 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102695496B (zh) 2009-12-23 2014-10-01 奇斯药制品公司 用于copd的气雾剂制剂
WO2011076841A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
DK2515855T6 (da) * 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
PT2515854E (pt) 2009-12-23 2014-05-27 Chiesi Farma Spa Formulação de aerossol para dpoc
PH12013502270A1 (en) * 2011-05-17 2014-01-27 Pearl Therapeutics Inc Compositions, methods & systems for respiratory delivery of two or more active agents
TN2016000262A1 (en) * 2013-12-30 2017-10-06 Chiesi Farm Spa Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination.
CA2935305C (en) * 2013-12-30 2022-07-12 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination

Also Published As

Publication number Publication date
MX2016008591A (es) 2016-09-26
US20150182459A1 (en) 2015-07-02
GEP20186870B (en) 2018-06-25
WO2015101575A1 (en) 2015-07-09
PH12016501269B1 (en) 2019-09-18
KR20160104042A (ko) 2016-09-02
IL246502A0 (en) 2016-08-31
AU2014375300B2 (en) 2019-10-24
AU2014375300A1 (en) 2016-07-14
HRP20180944T1 (hr) 2018-08-10
ES2666905T3 (es) 2018-05-08
EP3096737B1 (en) 2018-04-04
EA033228B1 (ru) 2019-09-30
US20170095444A1 (en) 2017-04-06
MA39154A1 (fr) 2017-08-31
MX368834B (es) 2019-10-18
PT3096737T (pt) 2018-04-27
EA201691127A1 (ru) 2016-12-30
EP3096737A1 (en) 2016-11-30
CL2016001652A1 (es) 2017-08-25
NZ721640A (en) 2021-02-26
PH12016501269A1 (en) 2016-08-15
US20160303044A1 (en) 2016-10-20
LT3096737T (lt) 2018-06-11
PL3096737T3 (pl) 2018-08-31
JP2017507168A (ja) 2017-03-16
ES2666905T4 (es) 2018-06-07
JP6826145B2 (ja) 2021-02-03
TN2016000262A1 (en) 2017-10-06
HUE039359T2 (hu) 2018-12-28
CN105848642A (zh) 2016-08-10
US10596149B2 (en) 2020-03-24
JP2019112458A (ja) 2019-07-11
ME03076B (me) 2019-01-20
MY176191A (en) 2020-07-24
BR112016014586A2 (pt) 2017-08-08
TR201809356T4 (tr) 2018-07-23
KR101865131B1 (ko) 2018-06-08
RS57269B1 (sr) 2018-08-31
SI3096737T1 (en) 2018-07-31
US10617669B2 (en) 2020-04-14
IL246502B (en) 2020-05-31
DK3096737T3 (en) 2018-06-25
CA2935302C (en) 2022-06-21
CN113143894A (zh) 2021-07-23
GEAP201814192A (en) 2018-02-26
CA2935302A1 (en) 2015-07-09
AR130238A2 (es) 2024-11-20
AR098983A1 (es) 2016-06-22
SG11201605309UA (en) 2016-07-28
JP6534397B2 (ja) 2019-06-26
NO3096737T3 (es) 2018-09-01
CY1120205T1 (el) 2018-12-12
UA117846C2 (uk) 2018-10-10
SA516371428B1 (ar) 2018-09-30

Similar Documents

Publication Publication Date Title
PE20161132A1 (es) Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol
PE20160997A1 (es) Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol
AR115897A2 (es) Composición farmacéutica para enfermedad pulmonar obstructiva crónica (epoc), frasco de aerosol que lo comprende, y método para rellenarlo
PE20070951A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
MX2021009476A (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
CL2012001668A1 (es) Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros.
AR104209A1 (es) Formulación y contenedores de aerosol, inhaladores y similares que contienen la formulación
RU2012125966A (ru) Комбинированное лечение хронического обструктивного заболевания легких
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
PE20181488A1 (es) Proceso para preparar una formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico
GEP20227418B (en) Combination therapy for copd
CL2012000327A1 (es) Composicion farmaceutica resistente a corrosion y estable para inhalador presurizado de dosis medida que contiene un ingrediente activo suspendido y otro disuelto, un haluro disuelto, un cosolvente, un propulsor, entre 0,1 y 10 % de agua, 0,0001 y 0,01 % de un acido organico y 0,01 a 0,3 % de agente suspensor insaturado; metodo de preparacion.
RU2012125965A (ru) Аэрозольная препаративная форма для лечения по поводу хронического обструктивного легочного заболевания
AR088273A1 (es) Composicion contenida dentro de un inhalador farmaceutico presurizado de dosis medida
AR054230A1 (es) Formulaciones farmaceuticas en aerosol para inhaladores de cartucho presurizados que comprenden un agente secuestrante
AR086252A1 (es) Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo
TH171993A (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล
NZ786610A (en) Stainless steel can for pressurised metered dose inhalers
TH171992A (th) องค์ประกอบสารละลายชนิดละอองลอยแบบอัดความดันที่เสถียรของการรวมกันของ ไกลโคไพร์โรเนียมโบรไมด์ และฟอร์โมเทอรอล
GEP20257784B (en) Stainles steel can for pressurised metered dose inhalers
GEAP202515973A (en) Stainles steel can for pressurised metered dose inhalers
NZ786610B2 (en) Stainless steel can for pressurised metered dose inhalers
TH127043A (th) ผลิตภัณฑ์รวมสำหรับบำบัด copd
AR085443A1 (es) Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero
AR100619A1 (es) COMPOSICIÓN FARMACÉUTICA QUE COMBINA INHIBIDORES DE FOSFOINOSÍTIDO 3-QUINASA d Y CORTICOESTEROIDES PARA EL TRATAMIENTO DE ENFERMEDADES CUTÁNEAS INMUNOAMPOLLOSAS